GLP-1 Agonist Obesity Deal Benchmarks 2026

Median Upfront

$935M

Range: $509M - $1.4B

Total Deal Value

$4.5B

Range: $2.9B - $6.1B

Royalty Rate

16.1% - 29.5%

Tiered up to 33.5%

Dev Milestones

$647M

Range: $438M - $857M

Model Your Deal

Market Analysis

GLP-1 receptor agonists have become the defining drug class of the decade. Semaglutide (Wegovy/Ozempic) generated $20B+ in annual revenue by 2025, making it the fastest drug to that milestone in pharma history. Tirzepatide (Mounjaro/Zepbound) achieved 22.5% weight loss in clinical trials, approaching bariatric surgery efficacy without the surgical risk.

Phase 2 GLP-1 agonist licensing deals for obesity carry median upfront payments of $935M (range $509M - $1.4B), with total deal values reaching $4.5B. The CSPC/AstraZeneca deal at $18.5B headline value and Carmot/Roche acquisition at $2.7B set the high-water marks for the category.

Oral GLP-1 formulations command significant premiums: $1.1B upfront vs $935M for injectables. The oral convenience advantage drives patient preference, primary care adoption, and payer formulary access — making oral GLP-1 assets the most sought-after in biopharma.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How much are GLP-1 obesity deals worth in 2026?

Phase 2 injectable GLP-1 deals average $4.5B total deal value with $935M upfront. Oral GLP-1 assets command 20-30% premiums, averaging $5.1B total value.

What royalty rates do GLP-1 obesity deals command?

GLP-1 obesity royalties range from 16.1%-29.5% base tier, escalating to 33.5% at peak sales. The $100B+ projected obesity market drives aggressive tiered royalty structures.

How do oral GLP-1 deals compare to injectable GLP-1 deals?

Oral GLP-1 deals command 20-30% premiums over injectable equivalents. Oral formulations average $1.1B upfront vs $935M for injectables, reflecting the oral convenience advantage for patient adherence and primary care adoption.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

GLP-1 Agonist Obesity Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Metabolic & Obesity Overview

Dual Incretin Deal Benchmarks

NASH/MASH Deal Benchmarks

Ready to Calculate Your Deal Terms?